Recovery
KPV
Lys-Pro-Val tripeptide (alpha-MSH 11-13)
KPV is a three-amino-acid fragment of alpha-melanocyte-stimulating hormone that has shown anti-inflammatory activity in lab and animal models. It is not FDA-approved, and its research is still largely preclinical.
Key facts
- Commonly discussed for: gut inflammation and wound healing.
- Evidence (D): The core evidence is cell-culture work and mouse colitis models (DSS, TNBS and transfer colitis) published in Gastroenterology and Inflammatory Bowel Diseases in 2008. No controlled human trials were found.
- FDA status: PCAC recommended. On July 23, 2026 the PCAC voted 8-6 (1 abstention) to recommend KPV for the 503A Bulks List for wound healing and inflammatory conditions; FDA must still publish a proposed rule; none appeared in the Federal Register as of October 1, 2026.
- Legitimate access: No clear legal route yet.
- Last reviewed: October 1, 2026.
Read the deep dives
Thinking about KPV?
Add it to your stack, then bring the list to a licensed provider. They can tell you whether it fits your health picture and what the legitimate options are. Peptiblox never sells peptides or links to sellers. Check the legal status tracker for the latest FDA changes.
Open my stack →Sources
- Dalmasso et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 2008
- Kannengiesser et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of IBD. Inflamm Bowel Dis, 2008
- McDermott Will & Schulte: PCAC backs majority of peptides in two-day public meeting (July 2026)
- Federal Register notice of PCAC meeting and uses under review (April 16, 2026)